News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Bridging Scientific Progress With Real-World Practice in SCLC Care

Jacob Sands, MD, associate chief of the Lowe Center for Thoracic Oncology, Oncology Medical Director of the International Patient Center, and physician at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

ByJacob Sands, MD

May 26th 2026

Dr Sands discusses the rapidly evolving treatment landscape for SCLC.

Alissa Cooper, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School

Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

ByAlissa J. Cooper, MD

April 30th 2026

Dr Cooper discusses recent advances that have reshaped the treatment paradigm for small cell lung cancer, particularly in the relapsed setting.

Ticiana Leal, MD, professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute

Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD

ByTiciana A. Leal, MD

March 31st 2026

Dr Leal discusses variability in community practice and evolving treatment strategies for patients with small cell lung cancer.

Misty D. Shields, MD, PhD, translational medical oncologist at Indiana University Health in Indianapolis

Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD

ByMisty D. Shields, MD, PhD

March 30th 2026

Dr Shields discusses the realities of treating patients with SCLC in the community setting and how emerging therapies are shaping care delivery.

Anne Chiang, MD, PhD

Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD

ByAnne Chiang, MD, PhD, Yale Cancer Center

February 27th 2026

Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.

Trending on OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC

GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates